<p>This is a summary of the European public assessment report (EPAR) for Spinraza. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Spinraza.</p><p>For practical information about using Spinraza, patients should read the package leaflet or contact their doctor or pharmacist.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.</p> </div>
Therapeutic Area (MeSH)
ATC Code
M09
ATC Item
N/A
Pharmacotherapeutic Group
Other nervous system drugs
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| nusinersen sodium | N/A | nusinersen sodium |
EMA Name
Spinraza
Medicine Name
Spinraza
Aliases
N/ANo risk management plan link.
